The Role of Elacridar, a P-gp Inhibitor, in the Re-Sensitization of PAC-Resistant Ovarian Cancer Cell Lines to Cytotoxic Drugs in 2D and 3D Cell Culture Models
International Journal of Molecular Sciences · 28.01.2025 · 26 (3) · 1124
DOI: 10.3390/ijms26031124 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.01.2025. Verfasst von Piotr Stasiak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biological Sciences, University of Zielona Góra, 65-417 Zielona Góra, Poland. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Ovarian Neoplasms, Tetrahydroisoquinolines, Acridines. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Center, National Science Centre, Kraków, Poland.
Abstract (Originalsprache)
Chemotherapy resistance is a significant barrier to effective cancer treatment. A key mechanism of resistance at the single-cell level is the overexpression of drug transporters in the ABC family, particularly P-glycoprotein (P-gp), which leads to multidrug resistance (MDR). Inhibitors of these transporters can help re-sensitize cancer cells to chemotherapeutics. This study evaluated elacridar (GG918 and GF120918), a potent third-generation P-gp inhibitor, for its ability to reverse MDR in paclitaxel (PAC)-resistant ovarian cancer cell lines. Sensitive and PAC-resistant cells were cultured in two-dimensional (2D) and three-dimensional (3D) models. MDR1 gene expression was analyzed using Q-PCR, and P-gp protein expression was examined via Western blot and immunofluorescence. Drug sensitivity was evaluated with MTT assays, and P-gp activity was analyzed by flow cytometry and fluorescence microscopy. Elacridar effectively inhibited P-gp activity and increased sensitivity to PAC and doxorubicin (DOX) in 2D cultures but not cisplatin (CIS). In 3D spheroids, P-gp activity inhibition was observed via Calcein-AM staining. However, no re-sensitization to PAC occurred and limited improvement was observed for DOX. These findings suggest that elacridar effectively inhibits P-gp in both 2D and 3D conditions. However, its ability to overcome drug resistance in 3D models is limited, highlighting the complexity of tissue-specific resistance mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biological Sciences, University of Zielona Góra, 65-417 Zielona Góra, Poland.
- The Doctoral School of Exact and Technical Sciences, University of Zielona Góra, 65-417 Zielona Góra, Poland.
- Institute of Health Sciences, Collegium Medicum, University of Zielona Góra, 65-417 Zielona Góra, Poland.
- Department of Histology and Embryology, Doctoral School, Poznan University of Medical Sciences, 61-701 Poznań, Poland.
- Department of Histology and Embryology, Poznan University of Medical Sciences, 61-701 Poznań, Poland.
ORCID-Profile: Piotr Stasiak, Agnieszka Anna Rawłuszko-Wieczorek, Jan Korbecki, Radosław Januchowski
Förderung
- National Science Center
- National Science Centre, Kraków, Poland
Zitieren
APA
Stasiak, P., Sopel, J., Lipowicz, J. M., Rawłuszko-Wieczorek, A. A., Korbecki, J., & Januchowski, R. (2025). The Role of Elacridar, a P-gp Inhibitor, in the Re-Sensitization of PAC-Resistant Ovarian Cancer Cell Lines to Cytotoxic Drugs in 2D and 3D Cell Culture Models. International Journal of Molecular Sciences, 26(3), 1124. https://doi.org/10.3390/ijms26031124
Vancouver
Stasiak P, Sopel J, Lipowicz JM, Rawłuszko-Wieczorek AA, Korbecki J, Januchowski R. The Role of Elacridar, a P-gp Inhibitor, in the Re-Sensitization of PAC-Resistant Ovarian Cancer Cell Lines to Cytotoxic Drugs in 2D and 3D Cell Culture Models. International Journal of Molecular Sciences. 2025;26(3):1124. doi:10.3390/ijms26031124
BibTeX
@article{Stasiak2025,
author = {Stasiak, Piotr and Sopel, Justyna and Lipowicz, Julia Maria and Rawłuszko-Wieczorek, Agnieszka Anna and Korbecki, Jan and Januchowski, Radosław},
title = {The Role of Elacridar, a P-gp Inhibitor, in the Re-Sensitization of PAC-Resistant Ovarian Cancer Cell Lines to Cytotoxic Drugs in 2D and 3D Cell Culture Models},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {3},
pages = {1124},
doi = {10.3390/ijms26031124}
}
EUVIMED